INTRODUCTION {#s1}
============

Colon polyps are outgrowths of the colon mucosa and can progress to colon cancer. Polyps with malignant potential are categorized as neoplastic polyps, whereas polyps that are considered to have no cancer risk are categorized as nonneoplastic. Each of these categories is further subdivided into multiple histological subtypes. The Peutz--Jeghers (PJ) polyp constitutes a rare subtype with a characteristic histological appearance showing tree-like branching of smooth muscle cells and lobular organization of colonic crypts ([@LINHARTMCS001610C24]). PJ polyps almost exclusively occur in the context of the Peutz--Jeghers syndrome, which is characterized by mucocutaneous hyperpigmentation and the development of multiple intestinal polyps in the first two to three decades of life. Peutz--Jeghers is an autosomal dominant disorder caused by pathogenic variants of the *STK11* gene located on human Chromosome 19p13 ([@LINHARTMCS001610C29]).

Even though PJ polyps are categorized as nonneoplastic, the disorder is associated with a 93% cancer risk ([@LINHARTMCS001610C16]), and the risk of colon cancer in Peutz--Jeghers patients has been estimated at 39% ([@LINHARTMCS001610C25]). Also, neoplastic transformation of PJ polyps has been documented ([@LINHARTMCS001610C4]). Contrary to the polyps associated with Peutz--Jeghers syndrome, however, the molecular pathology and malignant potential of solitary PJ polyps is unknown. Only one study reported molecular analysis of a solitary PJ polyp finding no loss of heterozygosity at the 19p13.3 locus and no mutation of *STK11* ([@LINHARTMCS001610C8]), suggesting that solitary PJ polyps constitute a separate entity. To further characterize the molecular pathology and malignant potential we here conducted the first comprehensive DNA sequencing and DNA methylation analysis of a solitary PJ polyp.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The patient complained of intermittent midabdominal pain that had started ∼6 mo prior to admission. In addition, he reported a recent change of bowel habits with intermittent loose stools, no loss of weight, and no rectal bleeding. Past medical history included coronary heart disease and chronic obstructive pulmonary disease. The family history was negative for gastrointestinal tumors. Outpatient colonoscopy had shown a pedunculated polyp located in the distal section of the sigmoid colon and sigmoid diverticulosis. The patient was then referred to our clinic for polypectomy. The age of the patient at the time of polypectomy was 77 yr.

At admission clinical examination and laboratory studies were unremarkable and mucocutaneous hyperpigmentation was not detectable. Repeat colonoscopy in our hospital confirmed sigmoid diverticulosis and a pedunculated polyp of the distal sigmoid colon located at 20 cm from the anocutaneous line with a diameter of ∼3 cm. No other polyps were detected by colonoscopy. The polyp was removed by an endoscopic snare and submitted for pathological assessment. Hematoxylin and eosin staining showed the characteristic lobular grouping of crypts surrounded by branching smooth muscle fibers ([Fig. 1](#LINHARTMCS001610F1){ref-type="fig"}). The fraction of epithelial cells in the polyp was estimated to be \>80%.

![A representative section of a solitary PJ polyp (hematoxylin and eosin stain). The image shows characteristic lobular grouping of crypts surrounded by branching smooth muscle fibers. Scale bar, 200 µm.](LinhartMCS001610_F1){#LINHARTMCS001610F1}

Genomic Analyses {#s2b}
----------------

Whole-genome sequencing was performed at 70× genome coverage, respectively, for the polyp sample and for a blood sample from the same patient ([Table 1](#LINHARTMCS001610TB1){ref-type="table"}). Data analysis identified 2079 high-confidence somatic single-nucleotide variants (SNVs), most of which correspond to C \> T substitutions in an ACG trinucleotide context. Allele frequencies show a sharp peak at 0.1, indicating that most of the mutations are nonclonal. This pattern is reflected in the subset of 17 missense variants ([Table 2](#LINHARTMCS001610TB2){ref-type="table"}). Notably, the ERBB3 p.P306H mutation has been described in the COSMIC (Catalogue of Somatic Mutations in Cancer) database and was also identified in a non-small-cell lung adenocarcinoma in our in-house tumor cohorts. Located in the growth factor receptor/furin-like cysteine-rich domain, it is annotated as pathogenic by various functional impact prediction tools.

###### 

Sequencing coverage of whole-genome sequencing

  Sample   Read pairs sequenced   Reads aligned   PCR duplicates   Average read coverage
  -------- ---------------------- --------------- ---------------- -----------------------
  Polyp    1,680,950,965          99.73%          8.70%            69.97×
  Blood    1,764,374,344          99.56%          8.50%            73.81×

PCR, polymerase chain reaction.

###### 

Somatic mutations in a solitary PJ polyp detected by whole-genome sequencing

  Chr   Position GRCh37   dbSNP ID      Ref. base   Alt. base   Gene         Variant type   Predicted effect   Coding DNA exchange         Amino acid exchange   Genotype   Allele freq.   COSMIC ID
  ----- ----------------- ------------- ----------- ----------- ------------ -------------- ------------------ --------------------------- --------------------- ---------- -------------- -------------
  1     38082222          rs200218812   C           T           *RSPO1*      Substitution   Missense           c.G220A                     p.V74I                het.       0.07           
  1     158622275                       C           A           *SPTA1*      Substitution   Missense           c.G3357T                    p.K1119N              het.       0.06           
  3     73432532                        G           A           *PDZRN3*     Substitution   Missense           C3185T                      p.S1062               het.       0.07           .
  4     156860666         rs199672156   C           T           *CTSO*       Substitution   Missense           c.G409A                     p.V137M               het.       0.10           
  5     52097492                        CGGA        C           *PELO*       Deletion       No frameshift      c.977_979del                p.326_327del          het.       0.05           
  5     52097497                        C           CT          *PELO*       Insertion      Frameshift         c.982_983insT               p.R328fs              het.       0.05           
  5     148753978                       C           T           *IL17B*      Substitution   Missense           c.G497A                     p.R166H               het.       0.08           
  6     102124509                       T           A           *GRIK2*      Substitution   Missense           c.T553A                     p.L185M               het.       0.06           
  7     95906629                        C           T           *SLC25A13*   Substitution   Missense           c.G91A                      p.G31S                het.       0.06           COSM3883588
  8     25745417                        C           T           *EBF2*       Substitution   Missense           c.G823A                     p.G275R               het.       0.07           
  8     67355035                        C           T           *ADHFE1*     Substitution   Missense           c.C100T                     p.P34S                het.       0.07           
  11    73179461                        A           G           *FAM168A*    Substitution   Missense           c.T59C                      p.M20T                het.       0.09           
  12    56482369                        C           A           *ERBB3*      Substitution   Missense           c.C917A                     p.P306H               het.       0.09           COSM4043445
  13    27257046          rs373084396   G           A           *WASF3*      Substitution   Missense           c.G1286A                    p.R429Q               het.       0.11           
  13    28589790                        T                       *FLT3*       Insertion      Frameshift         c.2597_2598ins GACCACCGAG   p.G866fs              het.       0.07           
  13    50141395                        C           A           *RCBTB1*     Substitution   Missense           c.G21T                      p.W7C                 het.       0.10           
  14    24045075                        C           A           *JPH4*       Substitution   Missense           c.G970T                     p.D324Y               het.       0.10           
  19    48533818                        C           T           *CABP5*      Substitution   Missense           c.G518A                     p.R173H               het.       0.09           COSM299924
  19    50393133                        C           T           *IL4I1*      Substitution   Missense           c.G1498A                    p.A500T               het.       0.09           
  19    52147182                        G           A           *SIGLEC14*   Substitution   Missense           c.C862T                     p.R288W               het.       0.10           

dbSNP, Database for Short Genetic Variations; COSMIC, Catalogue of Somatic Mutations in Cancer; het., heterozygous.

Analysis of mutational signatures ([@LINHARTMCS001610C1]) identified AC1 as the dominant contributor. This signature corresponds to the spontaneous deamination of 5-methylcytosine, correlating with the age of the patient. We did not find any signatures related to DNA mismatch repair, which is in line with the stable genomic profile. Copy-number analysis based on read depth plots and structural variation detection tools failed to reveal any reliable focal or large-scale somatic aberrations. We observed a subclonal loss of the Y Chromosome in both the blood and, to a lesser extent, the polyp. This phenomenon can be explained by age-related loss of Y in a fraction of white blood cells ([@LINHARTMCS001610C18]; [@LINHARTMCS001610C6]).

From the 42 high-confidence somatic insertions and deletions (indels) that were identified genome-wide, none fall into a coding gene or splice site, probably because of allele frequencies below the default reliability threshold. Lowering the threshold identified 243 indels, three of which were located in coding regions ([Table 2](#LINHARTMCS001610TB2){ref-type="table"}). The *FLT3* frameshift insertion is located in the protein kinase domain, just 30 amino acids from the hotspot position at D835.

Notably, neither somatic nor germline mutations or copy-number alterations were found to be present at the *STK11* locus, even though this gene is often found mutated in Peutz--Jeghers patients ([@LINHARTMCS001610C29]). The only deviation from the reference sequence is the common intronic variant rs4807008, for which the patient is homozygous. We could also not identify any rare or private coding germline SNV or indel in known cancer-predisposing genes. These results are consistent with the findings from the only other published study investigating the *STK11* mutation status of a solitary PJ polyp ([@LINHARTMCS001610C8]).

DNA Methylation Analyses {#s2c}
------------------------

Because our genomic analysis did not detect any clonal mutations, we also analyzed the epigenome of the polyp. To this end, we used array-based methylation profiling of 450,000 methylation sites in the human genome (Infinium HumanMethylation450 arrays). The same platform was also used by The Cancer Genome Atlas (TCGA) for the analysis of 373 colorectal tumors and 45 control colon mucosa samples. Principal component analysis of the combined data sets showed that the solitary PJ polyp clustered separately from the majority of the normal colonic mucosa samples ([Fig. 2](#LINHARTMCS001610F2){ref-type="fig"}A), thus indicating an aberrant methylome in the adenoma sample.

![Aberrant DNA methylation in a solitary PJ polyp. (*A*) Principal component analysis of all probes in the merged TCGA (The Cancer Genome Atlas) and polyp data set. (*B*) Identification of hyper- and hypomethylated probes in the PJ polyp. β values are colored from blue (β = 0) over white (β = 0.5) to red (β = 1). Probe annotation features are shown on the *right*. CGI, CpG island; P, promoter; B, gene body; IGR, intergenic region. (*C*) Methylation patterns of selected "tumor prone CpG islands" in TCGA normal colonic mucosa (N, *N* = 45), the PJ polyp (PJP, *N* = 1), and TCGA colorectal tumors (T, *N* = 373). Each column represents one probe of the CpG island, β values are indicated as in *B*. (*D*) Methylation pattern of the *STK11* locus. CpG island--associated probes are indicated by green bars; promoter-associated probes are indicated by the black bar.](LinhartMCS001610_F2){#LINHARTMCS001610F2}

To further analyze these methylation changes, methylation values of individual probes were compared between the polyp and the TCGA normal data set. This identified 306 hypermethylated probes and 11,276 hypomethylated probes ([Fig. 2](#LINHARTMCS001610F2){ref-type="fig"}B). Interestingly, the hypermethylated probes were strongly associated with CpG islands, whereas the hypomethylated probes were often associated with intergenic regions ([Fig. 2](#LINHARTMCS001610F2){ref-type="fig"}B). These features have been described as the defining hallmarks of the colon cancer methylome ([@LINHARTMCS001610C3]). We also identified "tumor prone CpG islands" ([@LINHARTMCS001610C3]) using the TCGA colorectal cancer data set and subsequently compared their methylation with the polyp data (see Methods). This identified several CpG islands that showed tumor-associated hypermethylation in the solitary PJ polyp ([Fig. 2](#LINHARTMCS001610F2){ref-type="fig"}C). Of note, no methylation changes were detected at the *STK11* locus ([Fig. 2](#LINHARTMCS001610F2){ref-type="fig"}D), indicating that the locus is not affected by a cancer-specific epigenetic mutation.

DISCUSSION {#s3}
==========

Solitary PJ polyps are a rare type of hamartomatous polyps of unknown etiology. Our report provides the first genome sequence of a solitary PJ polyp and reveals a number of genetic variants with relatively low allele frequencies (∼10%) and in genes that are not commonly associated with colorectal carcinogenesis. Consistent with a previous report ([@LINHARTMCS001610C8]), no genetic alterations were detected at the *STK11* locus, which is commonly associated with Peutz--Jeghers. These findings indicate that the molecular profile of solitary PJ polyps differs from Peutz--Jeghers syndrome. Our report also provides the first methylome analysis of a solitary PJ polyp and reveals moderate epigenetic alterations that are similar to the methylation changes of colorectal tumors. Together, our findings establish the first comprehensive genetic profile of a solitary PJ polyp.

Colorectal polyps are precursor lesions of colorectal cancer and are generally considered to evolve clonally from the colorectal mucosa ([@LINHARTMCS001610C26]). The absence of clonal mutations in the solitary PJ polyp therefore suggests that the initial signal for clonal expansion is not provided by genetic changes in epithelial cells but by other mechanisms. Indeed, our data can be interpreted to reflect a substantial intrapolyp heterogeneity for subclonal mutations, which is consistent with the "Big Bang" model of colorectal carcinogenesis ([@LINHARTMCS001610C21]). The acquisition of a tumor-driving mutation in a specific subclone could then represent the initiating event for tumor growth.

Interestingly, our methylome analysis revealed additional molecular alterations of the polyp genome. A comparative methylation pattern analysis with data sets from normal colorectal mucosa and colorectal tumor samples revealed moderate but clearly detectable epigenetic changes in the polyp that resemble the methylation changes commonly associated with colorectal cancer ([@LINHARTMCS001610C3]). More specifically, we identified "tumor-prone CpG islands" that showed a similar degree of hypermethylation in the polyp and in colorectal cancer. These findings are consistent with the notion that epigenetic changes represent early events during colorectal carcinogenesis ([@LINHARTMCS001610C9]).

It is well established that Peutz--Jeghers patients carry a significant cancer risk, and it has been shown that cancer can develop in PJ polyps ([@LINHARTMCS001610C15]). Accordingly, surveillance colonoscopy is recommended in affected individuals starting at age 8, and removal of polyps of \>5 mm is recommended ([@LINHARTMCS001610C22]). Contrary to the polyps from Peutz--Jeghers patients, solitary PJ polyps are considered to have no malignant potential ([@LINHARTMCS001610C17]). However, because solitary PJ polyps constitute a rare entity it is not possible to reliably determine malignant potential by clinical studies. Rather, cancer risk has to be extrapolated from molecular data. Our finding of tumor-like CpG island hypermethylation and genomic hypomethylation in a solitary PJ polyp supports the notion that such polyps do carry a cancer risk and should be removed.

METHODS {#s4}
=======

Pathology and DNA Isolation {#s4a}
---------------------------

The polyp was removed by colonoscopy using an endoscopic snare. Subsequently, a representative part of the sample was removed and placed into RNAlater solution for stabilization of nucleic acids. The remaining portion of the polyp was formalin fixed and paraffin embedded for pathological analysis. DNA was isolated using the QIAGEN Blood and Tissue Kit. Following hematoxylin and eosin staining of paraffin embedded sections pathological assessment of polyp morphology was conducted according to current guidelines ([@LINHARTMCS001610C19]).

Genomic Analyses {#s4b}
----------------

Each sample was sequenced on two lanes of an Illumina X-Ten platform (see [Table 1](#LINHARTMCS001610TB1){ref-type="table"} for sequencing coverages). Reads were mapped to the 1000 Genomes phase 2 assembly of the human reference genome GRCh37 (NCBI build 37.1, downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/phase2_reference_assembly_sequence) using a hardware-accelerated version of BWA (Burrows--Wheeler alignment) ([@LINHARTMCS001610C11]) version 0.7.8 mem with option -T 0. The sambamba package ([@LINHARTMCS001610C23]) version 0.4.6 and 0.5.9, respectively, was used for sorting and to mark polymerase chain reaction (PCR) duplicates during merging the per-lane BAM (binary alignment) files.

For detection of SNVs we used our in-house pipeline. The pipeline is based on SAMtools mpileup and BCFtools ([@LINHARTMCS001610C12]) version 0.1.19 with parameter adjustments to allow calling of somatic variants with low allele frequency using heuristic filtering as described previously ([@LINHARTMCS001610C7]). We applied Platypus ([@LINHARTMCS001610C20]) version 0.7.4 to identify short indels with a similar reliability scoring as for SNVs. After not detecting any coding indels with the default high-confidence threshold of 8, the value was lowered to 7 to allow also medium-confidence events with variant frequency of \<10% and allele bias at the same time. All mutations were annotated with ANNOVAR ([@LINHARTMCS001610C27]) version November 2014, using the GENCODE version 19 gene model. Additional information was retrieved by overlapping the genomic positions with dbSNP (Database for Short Genetic Variations) version 141, 1000 Genomes phase1 integrated calls 20101123, COSMIC version 71, and dbNSFP (Database for Nonsynonymous SNPs' Functional Predictions) version 2.9 ([@LINHARTMCS001610C13], [@LINHARTMCS001610C14]).

A supervised analysis of the genome-wide somatic SNVs for mutational signatures ([@LINHARTMCS001610C1]) was conducted with the R package YAPSA. A detailed description of the algorithm is provided elsewhere ([@LINHARTMCS001610C5]). We searched for structural variants with CREST ([@LINHARTMCS001610C28]) and applied in-house tools for copy-number identification.

DNA Methylation Analysis {#s4c}
------------------------

Available Infinium 450K raw data idat files from colon adenocarcinoma, rectal adenocarcinoma, and corresponding normal samples were downloaded from The Cancer Genome Atlas repository and preprocessed using Minfi ([@LINHARTMCS001610C2]). Probes located on the sex chromosomes, or probes that failed detection *P*-value testing in at least one sample, were removed from the analysis. Probes showing cross-reactivity to at least one distant site, and thus allowing a mismatch of one base in the probe sequence, were also eliminated. Finally, probes containing a SNP with an allele frequency of at least 0.01 and located a maximum of 5 bases away from the single-base extension (SBE) site were also removed. β values were extracted from the remaining probes.

Principal component analysis using the R package FactoMiner ([@LINHARTMCS001610C10]) was performed with the extracted and merged β values of the TCGA data set and the PJ polyp data. Differentially methylated probes between the TCGA normal data set and the PJ polyp were addressed by identifying the probes in the PJ polyp data with an absolute β-value difference of ≥0.1 from the mean β value of the TCGA normal data set and with an absolute β value greater than the mean β value plus three times the standard deviation of the TCGA normal data set.

Hypermethylated tumor-prone CpG islands were identified in the TCGA data set by averaging the β values of all probes per CpG island and comparing the result of the tumor and normal data using a two-sided *t*-test. CpG islands showing a β-value difference of ≥0.1 and a *P*-value of \<0.01, were considered hypermethylated in colorectal tumors.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Genome-sequencing data are available from the NCBI Sequence Read Archive (SRA; <https://www.ncbi.nlm.nih.gov/sra>) under the accession numbers SRR5028731 (polyp) and SRR5028722 (blood). Methylation data are available from the EBI-EMBL ArrayExpress database (<https://www.ebi.ac.uk/arrayexpress>/) under the accession number E-MTAB-5255.
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